This activity features presentations and downloadable slides highlighting the use of targeted therapies in gastrointestinal (GI) cancers.
1.0 AMA PRA Category 1 Credit(s)™
Jun 14, 2019
Jun 14, 2020
Abstract #2522: Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)
Featured Expert: Kohei Shitara, MD
Abstract #TPS2655: A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Featured Expert: Rui-Hua Xu, MD, PhD
Abstract #3507: Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs)
Featured Expert: Javier Sastre, MD
Abstract #LBA4007: Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study
Featured Expert: Josep Tabernero, MD, PhD
Javier Sastre, MDHC San Carlos
Kohei Shitara, MDNational Cancer Center Hospital East
Josep Tabernero, MD, PhDVall d’Hebron Institute of Oncology (VHIO)
Rui-Hua Xu, MD, PhDSun Yat-sen University Cancer Center
This activity is designed for clinicians who are oncologists and gastroenterologists and are involved in the diagnosis and management of patients with GI cancers.
After successful completion of this educational activity, participants should be able to:
- Have increased knowledge regarding the key data about targeted therapy for GI cancer including advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and colorectal cancer (CRC)
- Have greater competence related to applying key data from the conference to clinical practice, as appropriate for patients with advanced (G/GEJ) adenocarcinoma and CRC
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.0 hour(s)
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Sastre has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck, MSD, Pfizer, Roche, Sanofi, Servier, and Shire. He has also received speaking honoraria from Ipsen, Lilly, Merck, MSD, Pfizer, Roche, Servier, and Shire. He has received fees for traveling and accommodations from Ipsen and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Shitara has disclosed that he has received advisory/consulting fees from Astellas Pharma, Bristol-Myers Squibb, Lilly, MSD, Ono Pharmaceutical, Pfizer, and Takeda. He has received fees for non-CME/CE services from AbbVie, Novartis, and Yakult. He has performed contracted research for Astellas Pharma, Chugai Pharm, Daiichi Sankyo, Dainippon Sumitomo Pharma, Lilly, Ono Pharmaceutical, MSD, Medi Science, and Taiho Pharmaceutical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Tabernero has disclosed that he has received consulting fees from Array Biopharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai; Foundation Medicine; Genentech, Inc.; Genmab A/S; HalioDX SAS; Halozyme; Imugene Limited; Inflection Biosciences Limited; Ipsen; Kura Oncology; Lilly; MSD; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign SL; Rafael Pharmaceuticals; F. Hoffmann-La Roche Ltd; Roche Diagnostics; Sanofi; Seattle Genetics; Servier; Symphogen; Taiho; and VCN Biosciences. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Xu has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Dovey Ragoonath-Cameron, PhD (scientific content manager) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.